Advertisement
Canada markets close in 46 minutes

  • S&P/TSX

    21,748.82
    -39.66 (-0.18%)
     

  • S&P 500

    5,463.83
    -5.47 (-0.10%)
     

  • DOW

    39,132.06
    +19.90 (+0.05%)
     

  • CAD/USD

    0.7296
    -0.0027 (-0.37%)
     

  • CRUDE OIL

    80.79
    -0.04 (-0.05%)
     

  • Bitcoin CAD

    83,221.81
    -1,664.64 (-1.96%)
     

  • CMC Crypto 200

    1,264.93
    -18.86 (-1.47%)
     

  • GOLD FUTURES

    2,310.30
    -20.50 (-0.88%)
     

  • RUSSELL 2000

    2,014.75
    -7.60 (-0.38%)
     

  • 10-Yr Bond

    4.3160
    +0.0780 (+1.84%)
     

  • NASDAQ

    17,731.55
    +13.89 (+0.08%)
     

  • VOLATILITY

    12.58
    -0.26 (-2.03%)
     

  • FTSE

    8,225.33
    -22.46 (-0.27%)
     

  • NIKKEI 225

    39,667.07
    +493.92 (+1.26%)
     

  • CAD/EUR

    0.6831
    -0.0001 (-0.01%)
     
MARKETS LIVE BLOG:

STOCKS HIGHER WITH INVESTORS ON WATCH FOR CUES

Amazon stock crosses US$2 trillion market cap

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire
·1 min read

CAMBRIDGE, Mass., June 3, 2024 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 4 newly-hired employees options to purchase an aggregate of 76,000 shares of Akebia's common stock on May 31, 2024, as inducements material to such employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)

The options have an exercise price of $1.12 per share, which is equal to the closing price of Akebia's common stock on the grant date. The stock options vest over four years, with 25% of the shares vesting on the first anniversary of the grant date and the remaining 75% of shares vesting quarterly thereafter, in each case, subject to the new employee's continued service with Akebia. Each stock option has a 10-year term and is subject to the terms and conditions of Akebia's inducement award program and a stock option agreement covering the grant.

About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

ADVERTISEMENT

Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302162303.html

SOURCE Akebia Therapeutics, Inc.